FDA Restricts Cell Therapeutics Drug Trial Following Death
The U.S. Food and Drug Administration has restricted clinical studies of Cell Therapeutics Inc.'s experimental blood cancer drug tosedostat after a patient died during a trial, blocking new trial participants from...To view the full article, register now.
Already a subscriber? Click here to view full article